Skip to main content

Month: January 2024

Brunswick Starts Phase II Drilling at Mirage, Globex Royalty, Lithium Property

ROUYN-NORANDA, Jan. 22, 2024 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) have started “A Phase II drilling campaign at the Mirage (Lac Escale) project, located in the Eeyou-Istchee James Bay region of Quebec. The winter drill program is targeting extensions of known pegmatite dykes (MR-1 to MR-6) and new prospective outcrops that have yet to be drill-tested.” “The planned drill holes are distributed over the 2.8 kilometer known strike length to test the entire spodumene-bearing pegmatite dyke swarm”. Previous drilling intersected...

Continue reading

New composition of Ageas’s Executive Committee

New composition of Ageas’s Executive Committee Today Ageas announces upcoming organisational changes within its Executive Committee with the objective to align its governance model to the strategic ambitions of the Group. Ageas is reinforcing the Group’s current Executive Committee by including all its 4 business segments (Europe, Asia, Belgium, and Reinsurance), complemented by a newly created function of Managing Director Business Development. The latter function will be responsible for the development and implementation of the Group’s strategy, and for the further evolution of its footprint. The changes are being implemented to:better reflect the current business profile taking into account the evolving importance and size of the Group’s different activities. simplify and improve the integration of corporate and business decision...

Continue reading

Reverse share split registered

Oslo, Norway, 22 January 2024 Interoil Exploration and Production ASA (the “Company”) refers to the resolution made by the Company’s Extraordinary General Meeting on 18 December 2023 to do a reverse share split (share consolidation) of the Company’s shares in the ratio of 10:1 to meet Oslo Børs’ requirements of a minimum share value of NOK 1 per share, and the announcement of key information relating to the share consolidation published on 19 January 2024. The reverse share split has now been registered with the Norwegian Register of Business Enterprises. Following such registration, the Company’s registered share capital is NOK 100,672,140, divided into 20,134,428 shares, each with a par value of NOK 5.00. This information is subject to the disclosure requirements pursuant to Oslo Rule Book II for companies...

Continue reading

Clinical Nutrition Market Set to Soar Past USD 22.9 Billion by 2030

The global Clinical Nutrition market size is expected to reach USD 22.9 billion by 2030 and exhibit a CAGR of 5% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing prevalence of chronic diseases and disorders, growing geriatric population, rising awareness about the importance of proper nutrition in healthcare, advancements in medical research and technology, expanding product portfolios by key players in the market, government initiatives and policies promoting clinical nutrition, are fueling the Market’s growth. Westford, USA, Jan. 22, 2024 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Clinical Nutrition Market, personalized nutrition and nutrigenomics, plant-based and vegan clinical nutrition products, clean label and natural ingredients,...

Continue reading

Probiotics Market Size Worth USD 125.55 Billion in 2032 | Emergen Research

Rising adoption of IoT devices and solutions and increasing use of IoT solutions built on blockchain with smart contracts and Artificial Intelligence (AI) are key factors driving Probiotics Market revenue growth Vancouver, Jan. 22, 2024 (GLOBE NEWSWIRE) — The global probiotics market size was USD 57.80 Billion in 2022 and is expected to register a revenue CAGR of 8.1% during the forecast period. Growing awareness among customers about gut health, involvement of international organizations in probiotic product Research & Development (R&D), and increasing consumption of probiotics in food and drinks are some of the key factors driving market revenue growth. Growing awareness among customers regarding gut health is a key factor driving market revenue growth. Consumption of probiotic-rich foods and the use of probiotic supplements...

Continue reading

GYRODYNE ANNOUNCES RECORD DATE FOR PROPOSED RIGHTS OFFERING

ST. JAMES, N.Y., Jan. 22, 2024 (GLOBE NEWSWIRE) — Gyrodyne, LLC (“Gyrodyne” or the “Company”) (NASDAQ: GYRO), an owner and manager of a diversified portfolio of real estate properties, today announced that the record date for its proposed rights offering is January 29, 2024 at 5:00 p.m. Eastern Time (the “Record Date”). As previously announced, the Company intends to raise up to $5 million in aggregate gross proceeds by way of a rights offering where its existing shareholders as of the Record Date will be granted rights to purchase shares of the Company’s common stock (the “Rights Offering”). The Company filed a registration statement (File No. 333-276312) (the “Registration Statement”) with respect to the proposed Rights Offering with the Securities and Exchange Commission (the “SEC”) on December 29, 2023.  In the Rights Offering,...

Continue reading

Remsleep Holdings Inc.’s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)

TAMPA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) — RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) has received a response to the company’s 510(K) submission K233415. The agency has determined that additional information is required. The agency has asked for additional information regarding Administrative Information, Device Description, Substantial Equivalence (SE), Labeling, Biocompatibility, and Performance testing. All these questions can be answered, and we are in the process of responding with the answers. The agency has also requested additional Shelf-Life testing for DeltaWave packaging. We are in the process of initiating accelerated Shelf-Life testing for the DeltaWave packaging. This request was a surprise to...

Continue reading

Form 8 (DD) – GCP Asset Backed Income Fund Limited

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: Foresight Group LLP(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree GCP Asset Backed Income Fund Limited(d)        Status of person making the disclosure:         e.g. offeror, offeree, person acting in concert with...

Continue reading

Peripheral Neuropathy Market Size Worth USD 8.54 Billion in 2032 | Emergen Research

Rise in peripheral neuropathy cases, the increased prevalence of chronic illnesses, and increasing number of pipeline drugs are some of the key factors driving Peripheral Neuropathy market revenue growth Vancouver, Jan. 22, 2024 (GLOBE NEWSWIRE) — The global peripheral neuropathy market size was USD 3.61 Billion in 2022 and is expected to register a revenue CAGR of 9.0% during the forecast period. Rise in peripheral neuropathy cases, the increased prevalence of chronic illnesses, and increasing number of pipeline drugs are some of the key factors driving market revenue growth.Increasing number of pipeline drugs is also a major factor expected to continue to drive adoption of peripheral neuropathy, due to large unfilled medical need and the possibility of novel, efficient treatments for peripheral neuropathy. Drugs categorized as...

Continue reading

Bitcoin Depot Places Order for 500 New BTM Kiosks from Kiosk Provider Genmega

BTM Acquisition Will Support the Company’s Bold Expansion Strategy as North America’s Market Share Leader ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot (“Bitcoin Depot” or the “Company”) (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced the purchase order of 500 new Bitcoin ATM kiosks from Genmega, a leading manufacturer and provider of ATM and Kiosk solutions with well over 150,000 units deployed worldwide. The Company plans to strategically deploy these units as part of its ongoing expansion efforts throughout 2024 and beyond. “The purchase order for these kiosks is significant as it demonstrates our ongoing commitment to a bold, strategic, and measured expansion this year,” said Bitcoin Depot CEO Brandon Mintz. “We are deeply committed to delivering a seamless and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.